4:49 PM
 | 
Feb 11, 2013
 |  BC Extra  |  Clinical News

Amgen, UCB discontinue AMG 785 for fractures

Amgen Inc. (NASDAQ:AMGN) and partner UCB Group (Euronext:UCB) discontinued development of romosozumab ( AMG 785) to improve fracture healing. The partners made the decision after top-line data showed the compound missed the primary endpoint of improving time to...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >